Clinical Trial Update: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating whether lowering lipoprotein(a) with pelacarsen (TQJ230) reduces major cardiovascular events in patients with atherosclerotic card…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cardiovascular Disease and Lipoprotein(a) | Phase 3 | Status: ACTIVE_NOT_RECRUITING